ClinicalTrials.gov
ClinicalTrials.gov Menu

Mirtazapine Plus Gemcitabine Versus Gemcitabine in Metastasis Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01598584
Recruitment Status : Withdrawn (Gemcitabine is not the first choice for most pancreatic cancer patients nowdays)
First Posted : May 15, 2012
Last Update Posted : September 28, 2015
Sponsor:
Information provided by (Responsible Party):
Tianjin Medical University Cancer Institute and Hospital

No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Recruitment Status : Withdrawn
  Estimated Primary Completion Date : December 2015
  Estimated Study Completion Date : December 2015